Who are FVIII Replacement's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Moroctocog alfa (AF-CC), Recombinant Human Coagulation FVIII, OBIZUR, Recombinant Factor VIII (rAHF), Coagulation Factor VIII, von Willebrand factor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fviii-replacement.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

FVIII Replacement — Competitive Intelligence Brief

FVIII Replacement (FVIII Replacement) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Coagulation factor replacement. Area: Rare Disease.

phase 2 Coagulation factor replacement Factor VIII Rare Disease Small molecule Live · refreshed every 30 min

Target snapshot

FVIII Replacement (FVIII Replacement) — Hoffmann-La Roche. Recombinant FVIII replacement to correct FVIII deficiency

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FVIII Replacement TARGET	FVIII Replacement	Hoffmann-La Roche	phase 2	Coagulation factor replacement	Factor VIII
Moroctocog alfa (AF-CC)	Moroctocog alfa (AF-CC)	Pfizer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Recombinant Human Coagulation FVIII	Recombinant Human Coagulation FVIII	Sinocelltech Ltd.	marketed	Coagulation factor replacement therapy	Coagulation Factor VIII
OBIZUR	OBIZUR	Baxalta now part of Shire	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Recombinant Factor VIII (rAHF)	Recombinant Factor VIII (rAHF)	Baxalta now part of Shire	marketed	Recombinant clotting factor	Coagulation Factor VIII
Coagulation Factor VIII	Coagulation Factor VIII	Beijing Children's Hospital	marketed	Coagulation factor replacement	Coagulation Factor VIII (antihemophilic factor)
von Willebrand factor	von Willebrand factor	National Center for Research Resources (NCRR)	marketed	Coagulation factor replacement	Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Coagulation factor replacement class)

Beijing Children's Hospital · 1 drug in this class
Bioverativ Therapeutics Inc. · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
National Center for Research Resources (NCRR) · 1 drug in this class
Takeda · 1 drug in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FVIII Replacement — Competitive Intelligence Brief. https://druglandscape.com/ci/fviii-replacement. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab